Amgen falls short in Epogen patent appeal but Pfizer stumble delays competition
admin 11th August 2017 Uncategorised 0A loss in appeals for Amgen doesn’t mean its blockbuster anemia med Epogen will face competition from a Pfizer biosimilar right away. That’s because Pfizer’s candidate stumbled at the FDA in June. About $1.28 billion in revenue is at stake.
More: Amgen falls short in Epogen patent appeal but Pfizer stumble delays competition
Source: fierce